Actavis acquires Indian manufacturing plant
Acquisition increases low cost manufacturing capability
Grandix provides Actavis with its own low cost manufacturing capability in India and a facility from which to develop and manufacture products for the US and key markets in Europe. Actavis also intends to use the facility as a manufacturing site to develop and re-launch older products as many of these products need lower cost base to be competitive in the international marketplace.
Actavis intends to increase the manufacturing capacity of the plant to approximately 4 billion tablets over the next 18 months and strengthen the development and regulatory affairs units.
Actavis has opened a new API development facility in India, with the aim of developing 10-15 products a year and the unit has already started development of the first ten. The new site is 1000 sqm and over 50 specialists have already been hired.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.